Automate Your Wheel Strategy on ABBV
With Tiblio's Option Bot, you can configure your own wheel strategy including ABBV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABBV
- Rev/Share 32.4474
- Book/Share 0.8269
- PB 231.11
- Debt/Equity 49.2176
- CurrentRatio 0.7602
- ROIC 0.1793
- MktCap 327879168000.0
- FreeCF/Share 8.7019
- PFCF 21.3116
- PE 78.2303
- Debt/Assets 0.5133
- DivYield 0.0344
- ROE 0.9559
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ABBV | Citigroup | Buy | Neutral | -- | $205 | May 14, 2025 |
| Initiation | ABBV | Cantor Fitzgerald | -- | Overweight | -- | $210 | April 22, 2025 |
| Resumed | ABBV | BofA Securities | -- | Neutral | -- | $191 | Dec. 10, 2024 |
| Downgrade | ABBV | Daiwa Securities | Outperform | Neutral | -- | $180 | Dec. 5, 2024 |
| Initiation | ABBV | Bernstein | -- | Market Perform | -- | $203 | Oct. 17, 2024 |
News
Final Trades: JPMorgan, Meta, Abbvie and Gap
Published: May 30, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Contact The Gross Law Firm by June 3, 2025 Deadline to Join Class Action Against Cerevel Therapeutics Holdings, Inc.(ABBV)
Published: May 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).
Read More
AbbVie Stock Down Around 13% in 3 Months: Time to Buy the Dip?
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
ABBV drops 12.6% in three months, but rising Skyrizi and Rinvoq sales, pipeline strength, and 2025 growth outlook support staying invested.
Read More
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Read More
Lost Money on Cerevel Therapeutics Holdings, Inc. (ABBV)? Urged to Join Class Action Before June 3, 2025 - Contact Levi & Korsinsky
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cerevel-therapeutics-holdings-inc-lawsuit-submission-form?prid=150335&wire=1&utm_campaign=22 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ABBV
Published: May 23, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 23, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud.
Read More
Levi & Korsinsky Notifies Shareholders of Cerevel Therapeutics Holdings, Inc. (ABBV) of a Class Action Lawsuit and an Upcoming Deadline
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud.
Read More
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights - ABBV
Published: May 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights – ABBV
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).
Read More
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cerevel-therapeutics-holdings-inc-lawsuit-submission-form?prid=149485&wire=1 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc. (ABBV) Shareholders
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit.
Read More
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact The Gross Law Firm about pending Class Action - ABBV
Published: May 19, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 19, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
The Only 5 ETFs You Need to Build Wealth for Retirement
Published: May 19, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Dividend stocks are a foundational building block for creating a retirement portfolio, offering a reliable income stream and potential for capital appreciation.
Read More
Shareholders That Lost Money on Cerevel Therapeutics Holdings, Inc.(ABBV) Should Contact Levi & Korsinsky about Pending Class Action - ABBV
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 19, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cerevel-therapeutics-holdings-inc-lawsuit-submission-form?prid=149127&wire=1 or contact Joseph E. Levi, Esq.
Read More
Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut.
Published: May 18, 2025 by: The Motley Fool
Sentiment: Positive
Dividend stocks can be a smart way to generate steady income, especially in uncertain markets. However, not all dividend payers are created equal.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit – ABBV
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit.
Read More
Is It Time To Buy AbbVie Stock At $180?
Published: May 16, 2025 by: Forbes
Sentiment: Positive
AbbVie (NYSE:ABBV) stock has garnered recent attention following the FDA approval of Emrelis for adults with previously treated lung cancer who exhibit an overabundance of the c-Met protein. This protein is known to promote tumor growth and resistance to certain therapies.
Read More
June 3, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ABBV
Published: May 16, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud.
Read More
The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – ABBV
Published: May 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).
Read More
AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Following the approval, ABBV's Emrelis becomes the first FDA-approved therapy for previously treated advanced NSCLC patients with high c-Met protein overexpression.
Read More
AbbVie Inc. (ABBV) Presents at BofA Securities 2025 Healthcare Conference (Transcript)
Published: May 14, 2025 by: Seeking Alpha
Sentiment: Neutral
AbbVie Inc. (NYSE:ABBV ) BofA Securities 2025 Healthcare Conference May 14, 2025 1:00 PM ET Company Participants Jeff Stewart - EVP and Chief Commercialization Officer Roopal Thakkar - EVP and R&D, Chief Scientific Officer Scott Reents - EVP and CFO Conference Call Participants Tim Anderson - Bank of America Tim Anderson Thanks for joining us for this next session. I'm Tim Anderson, the U.S. large-cap pharma and biotech analyst at Bank of America.
Read More
Lost Money on Cerevel Therapeutics Holdings, Inc. (ABBV)? Contact Levi & Korsinsky Before June 3, 2025 to Join Class Action
Published: May 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cerevel-therapeutics-holdings-inc-lawsuit-submission-form?prid=148519&wire=1&utm_campaign=12 or contact Joseph E. Levi, Esq.
Read More
US FDA approves AbbVie's drug for a type of lung cancer
Published: May 14, 2025 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received previous treatment, the drugmaker said on Wednesday.
Read More
U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression
Published: May 14, 2025 by: PRNewsWire
Sentiment: Neutral
– EMRELIS is the first and only treatment approved for previously treated advanced NSCLC patients with high c-Met protein overexpression who often face poor prognosis and have limited treatment options – Lung cancer remains the leading cause of cancer-related deaths throughout the worl d1 NORTH CHICAGO, Ill. , May 14, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that EMRELIS™ (telisotuzumab vedotin-tllv) has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (OE) who have …
Read More
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Pharma Stock Regeneron Is a Buy, Says Citi. But Be Cautious on AbbVie, Merck.
Published: May 14, 2025 by: Barrons
Sentiment: Positive
Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen next.
Read More
Levi & Korsinsky Notifies Shareholders of Cerevel Therapeutics Holdings, Inc.(ABBV) of a Class Action Lawsuit and an Upcoming Deadline
Published: May 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit.
Read More
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights – ABBV
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).
Read More
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
Read More
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc.(ABBV) Shareholders
Published: May 12, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
About AbbVie Inc. (ABBV)
- IPO Date 2013-01-02
- Website https://www.abbvie.com
- Industry Drug Manufacturers - General
- CEO Mr. Robert A. Michael CPA
- Employees 55000